Stock Events

Stock Events

Hillstream BioPharma 

$0.24
28
+$0.01+5.66% Friday 21:59

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
2.73M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

29NovExpected
Q2 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q2 2023
Q3 2023
-0.18
-0.05
0.09
0.22
Expected EPS
-0.05
Actual EPS
0

Financials

-Profit Margin
Unprofitable
2020
2021
2022
0Revenue
-8.47MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HILS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna, Inc. is a competitor because it also focuses on mRNA-based therapies, potentially overlapping with Tharimmune's immunotherapy approaches.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE operates in the field of mRNA technology for developing vaccines and therapeutics, directly competing with Tharimmune's technology platform.
Novavax
NVAX
Mkt Cap1.36B
Novavax, Inc. competes in the vaccine development space, particularly in the development of vaccines for infectious diseases, which may overlap with Tharimmune's focus areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio in vaccines and biopharmaceuticals, making it a competitor in various therapeutic areas that Tharimmune may target.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is involved in the development of antiviral drugs and other treatments that could compete with Tharimmune's immunotherapeutic approaches.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is known for its work in immunology and infectious diseases, areas that Tharimmune may also be exploring.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a diverse biopharmaceutical portfolio, including treatments for cancer and other diseases, potentially competing with Tharimmune's research and development.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson operates in various healthcare sectors, including pharmaceuticals with a focus on immunology, making it a competitor to Tharimmune.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. has a strong presence in the development of vaccines and cancer therapies, areas that may intersect with Tharimmune's interests.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is involved in the development of vaccines and treatments for immune system diseases, competing with Tharimmune in the immunotherapy space.

About

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Show more...
CEO
Mr. Sireesh Appajosyula Pharm.D.
Employees
2
Country
US
ISIN
US4327051011

Listings

XNAS
US
THAR
BOATS
BOATS
THAR.BOATS
XNAS
US
CNTN
MX
MX
CNTN.MX

0 Comments

Share your thoughts

FAQ

What is Hillstream BioPharma stock price today?▼
The current price of HILS is $0.24 USD — it has increased by +5.66% in the past 24 hours. Watch Hillstream BioPharma stock price performance more closely on the chart.
What is Hillstream BioPharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Hillstream BioPharma stocks are traded under the ticker HILS.
What is Hillstream BioPharma market cap?▼
Today Hillstream BioPharma has the market capitalization of 2.73M
What were Hillstream BioPharma earnings last quarter?▼
HILS earnings for the last quarter are 0 USD per share, whereas the estimation was -0.05 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Hillstream BioPharma revenue for the last year?▼
Hillstream BioPharma revenue for the last year amounts to 0 USD.
What is Hillstream BioPharma net income for the last year?▼
HILS net income for the last year is -8.47M USD.
How many employees does Hillstream BioPharma have?▼
As of April 01, 2026, the company has 2 employees.
In which sector is Hillstream BioPharma located?▼
Hillstream BioPharma operates in the Health Care sector.
When did Hillstream BioPharma complete a stock split?▼
Hillstream BioPharma has not had any recent stock splits.
Where is Hillstream BioPharma headquartered?▼
Hillstream BioPharma is headquartered in Bridgewater, US.